Back to results
US 2026/0028348 A1Published application
Modulators of tnf-alpha activity
AssigneeForward Therapeutics, Inc.
InventorToufike KANOUNI
Life of this patent
Estimating the term…
Abstract
Provided herein are inhibitors of TNF-α, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF-α inhibitory compounds for the treatment of diseases or disorders.
Claims52
A compound of Formula (I), or pharmaceutically acceptable salt, solvate, or N-oxide thereof:
- wherein,
- W is N or C—R4;
- X is N, C—F, or C—H;
- Y1 is N, C—F, or C—H;
- Y2 is N, C—F, or C—H;
- Y3 is N, C—F, or C—H;
- Z1 is N or C—H;
- Z2 is N or C—H;
- Z3 is N or C—H;
- A is CR5R6, or N—R9;
- B is CR7R8, or N—R10;
- C is —CH2—, —CH2CH2—, —NH—, —O—, —OCH2—, or —CH2O—;
- R1 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, or optionally substituted C4-C7 cycloalkylalkyl;
- R2 is hydrogen, or optionally substituted C1-C4 alkyl;
- R3 is hydrogen, methyl, or halogen;
- R4 is hydrogen, halogen, or optionally substituted C1 alkyl;
- R5 is —OH, —NH2, or —NH(optionally substituted C1-C6 alkyl);
- or optionally, R5 and R6 are both —OH and join to form an oxo group;
- R6 is hydrogen, —OH, or optionally substituted C1-C6 alkyl;
- or optionally, R6 and R8 are both optionally substituted C1-C6 alkyl and join to form a ring;
- R7 is hydrogen, —OH, or optionally substituted C1-C6 alkyl;
- or optionally, R7 and R8 are both —OH and join to form an oxo group;
- R8 is hydrogen, —OH, or optionally substituted C1-C6 alkyl;
- R9 is hydrogen, or optionally substituted C1-C6 alkyl;
- and
- R10 is hydrogen, or optionally substituted C1-C6 alkyl.
23 more elements
A compound of Formula (Ia), or pharmaceutically acceptable salt, solvate, or N-oxide thereof:
- wherein,
- W is N or C—R4;
- X is N, C—F, or C—H;
- Y1 is N, C—F, or C—H;
- Y2 is N, C—F, or C—H;
- Y3 is N, C—F, or C—H;
- Z1 is N or C—H;
- Z2 is N or C—H;
- Z3 is N or C—H;
- A is CR5R6, or N—R9;
- B is CR7R8, or N—R10;
- C is —CH2—, —CH2CH2—, —NH—, —O— or —CH2O—;
- R1 is selected from hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, or optionally substituted C4-C7 cycloalkylalkyl;
- R2 is hydrogen, or optionally substituted C1-C4 alkyl;
- R3 is hydrogen or halogen;
- R4 is hydrogen, halogen, or optionally substituted C1 alkyl;
- R5 is —OH, —NH2, or —NH(optionally substituted C1-C6 alkyl);
- or optionally, R5 and R6 are both —OH and join to form an oxo group;
- R6 is hydrogen, —OH, or optionally substituted C1-C6 alkyl;
- or optionally, R6 and R8 are both optionally substituted C1-C6 alkyl and join to form a ring;
- R7 is hydrogen, —OH, or optionally substituted C1-C6 alkyl;
- or optionally, R7 and R8 are both —OH and join to form an oxo group;
- R8 is hydrogen, —OH, or optionally substituted C1-C6 alkyl;
- R9 is hydrogen, or optionally substituted C1-C6 alkyl;
- and
- R10 is hydrogen, or optionally substituted C1-C6 alkyl.
23 more elements
A compound described in Table 1, or pharmaceutically acceptable salt, solvate, or N-oxide thereof.
A compound described in Table 2, or pharmaceutically acceptable salt, solvate, or N-oxide thereof.
Dependencies are inferred from the claim text.